Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.

Shaw RH, Greenland M, Stuart ASV, Aley PK, Andrews NJ, Cameron JC, Charlton S, Clutterbuck EA, Collins AM, Darton T, Dinesh T, Duncan CJA, Faust SN, Ferreira DM, Finn A, Goodman AL, Green CA, Hallis B, Heath PT, Hill H, Lambe T, Libri V, Lillie PJ, Morey E, Mujadidi YF, Payne R, Plested EL, Provstgaard-Morys S, Ramasamy MN, Ramsay M, Read RC, Robinson H, Screaton GR, Singh N, Turner DPJ, Turner PJ, White R, Nguyen-Van-Tam JS, Liu X, Snape MD, Com-COV2 Study Group

Open source

DOI
10.1016/j.jinf.2023.03.027
Published
2023 Jun
Container
The Journal of infection
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.jinf.2023.03.027,
  title = {Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.},
  author = {Shaw RH and Greenland M and Stuart ASV and Aley PK and Andrews NJ and Cameron JC and Charlton S and Clutterbuck EA and Collins AM and Darton T and Dinesh T and Duncan CJA and Faust SN and Ferreira DM and Finn A and Goodman AL and Green CA and Hallis B and Heath PT and Hill H and Lambe T and Libri V and Lillie PJ and Morey E and Mujadidi YF and Payne R and Plested EL and Provstgaard-Morys S and Ramasamy MN and Ramsay M and Read RC and Robinson H and Screaton GR and Singh N and Turner DPJ and Turner PJ and White R and Nguyen-Van-Tam JS and Liu X and Snape MD and Com-COV2 Study Group},
  year = {2023},
  journal = {The Journal of infection},
  doi = {10.1016/j.jinf.2023.03.027},
  url = {https://doi.org/10.1016/j.jinf.2023.03.027}
}

RIS

TY  - JOUR
TI  - Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
AU  - Shaw RH
AU  - Greenland M
AU  - Stuart ASV
AU  - Aley PK
AU  - Andrews NJ
AU  - Cameron JC
AU  - Charlton S
AU  - Clutterbuck EA
AU  - Collins AM
AU  - Darton T
AU  - Dinesh T
AU  - Duncan CJA
AU  - Faust SN
AU  - Ferreira DM
AU  - Finn A
AU  - Goodman AL
AU  - Green CA
AU  - Hallis B
AU  - Heath PT
AU  - Hill H
AU  - Lambe T
AU  - Libri V
AU  - Lillie PJ
AU  - Morey E
AU  - Mujadidi YF
AU  - Payne R
AU  - Plested EL
AU  - Provstgaard-Morys S
AU  - Ramasamy MN
AU  - Ramsay M
AU  - Read RC
AU  - Robinson H
AU  - Screaton GR
AU  - Singh N
AU  - Turner DPJ
AU  - Turner PJ
AU  - White R
AU  - Nguyen-Van-Tam JS
AU  - Liu X
AU  - Snape MD
AU  - Com-COV2 Study Group
PY  - 2023
JO  - The Journal of infection
DO  - 10.1016/j.jinf.2023.03.027
UR  - https://doi.org/10.1016/j.jinf.2023.03.027
ER  -

APA

RH, S., M, G., ASV, S., PK, A., NJ, A., JC, C., S, C., EA, C., AM, C., T, D., T, D., CJA, D., SN, F., DM, F., A, F., AL, G., CA, G., B, H., PT, H., H, H., T, L., V, L., PJ, L., E, M., YF, M., R, P., EL, P., S, P., MN, R., M, R., RC, R., H, R., GR, S., N, S., DPJ, T., PJ, T., R, W., JS, N., X, L., MD, S., & Group, C. S. (2023). Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.. The Journal of infection. https://doi.org/10.1016/j.jinf.2023.03.027

Source records